Literature DB >> 9007587

Quantitative molecular monitoring of HIV-1 RNA during antiretroviral therapy.

A Lafeuillade1, C Poggi, P Pellegrino, N Profizi.   

Abstract

Plasma HIV-1 RNA testing was used to monitor 43 HIV-1 infected patients newly placed on antiretroviral therapy or whose therapy had been recently changed. A polymerase chain reaction kit was used to measure HIV-1 RNA in clinical samples or frozen plasma. The cutoff of this test was 200 RNA copies/ml. The first group (11 patients) was stable on long-term zidovudine monotherapy when switched to stavudine. The HIV-1 RNA of three patients who had a regular decline in CD4+ T cell count did not change despite this switch, with a mean follow-up of 630 days. The HIV-1 RNA copy numbers of eight patients whose CD4+ T cell counts were stable declined an average of 0.53 log10 between days 90 and 650. The second group (14 patients) was on long-term zidovudine monotherapy and had declining CD4+ T cell counts over the past 6 months. Lamivudine was added to this regimen on day 0. HIV-1 RNA copy number decreased rapidly within 30 d, reaching -0.86 log10 on day 90, and this effect was maintained thereafter, with a mean follow-up of 161 days. There was a concomitant mean gain of +33 CD4+ T cells on day 90. The third group (nine patients) had never received anti-retroviral therapy and was given zidovudine+didanosine. HIV-1 RNA copy number decreased in all cases but one, reaching -1.31 log10 on day 150. This decrease was transient in three cases. The last group (nine patients) had also not had previous anti-retroviral therapy and was given zidovudine + didanosine + lamivudine in combination. HIV-1 RNA copy numbers declined rapidly in all cases, to below the cutoff in eight cases within a mean period of 50.5 days. The CD4+ cell counts increased by 164 cells/microliter on day 14 and by 201 cells/microliter on day 180. The response to therapy of the total population of 43 patients varied according to cases. The relative changes in p24 antigen compared to HIV-1 RNA also differed between patients. Measurement of HIV-1 viremia appears to be a valuable tool in current practice for individualizing therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9007587     DOI: 10.1007/bf01713040

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  34 in total

1.  Combination superior to zidovudine in Delta trial.

Authors:  V Choo
Journal:  Lancet       Date:  1995-09-30       Impact factor: 79.321

2.  Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count.

Authors:  C Loveday; A Hill
Journal:  Lancet       Date:  1995-03-25       Impact factor: 79.321

3.  Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection.

Authors:  J Mulder; N McKinney; C Christopherson; J Sninsky; L Greenfield; S Kwok
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

4.  Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy.

Authors:  P F Lin; H Samanta; R E Rose; A K Patick; J Trimble; C M Bechtold; D R Revie; N C Khan; M E Federici; H Li
Journal:  J Infect Dis       Date:  1994-11       Impact factor: 5.226

5.  Human immunodeficiency virus type 1 (HIV-1) viremia changes and development of drug-related mutations in patients with symptomatic HIV-1 infection receiving alternating or simultaneous zidovudine and didanosine therapy.

Authors:  E Kojima; T Shirasaka; B D Anderson; S Chokekijchai; S M Steinberg; S Broder; R Yarchoan; H Mitsuya
Journal:  J Infect Dis       Date:  1995-05       Impact factor: 5.226

6.  Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay.

Authors:  C Pachl; J A Todd; D G Kern; P J Sheridan; S J Fong; M Stempien; B Hoo; D Besemer; T Yeghiazarian; B Irvine
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1995-04-15

7.  Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

Authors:  W A O'Brien; P M Hartigan; D Martin; J Esinhart; A Hill; S Benoit; M Rubin; M S Simberkoff; J D Hamilton
Journal:  N Engl J Med       Date:  1996-02-15       Impact factor: 91.245

8.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

9.  Natural history of HIV-1 cell-free viremia.

Authors:  D R Henrard; J F Phillips; L R Muenz; W A Blattner; D Wiesner; M E Eyster; J J Goedert
Journal:  JAMA       Date:  1995-08-16       Impact factor: 56.272

10.  The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.

Authors:  J L Fahey; J M Taylor; R Detels; B Hofmann; R Melmed; P Nishanian; J V Giorgi
Journal:  N Engl J Med       Date:  1990-01-18       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.